Midatech Pharma plc
LSE: MTPH.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Stephen A. Stamp
- Employees
- 20
- Headquarters
- Cardiff, United Kingdom
- IPO year
- 2014
- Market cap
- £31.2M
- Website
- https://www.midatechpharma.com
Loading MTPH…
Loading profile data…Frequently asked questions about MTPH
What does Midatech Pharma plc (MTPH.L) do?
Midatech Pharma plc, a drug delivery technology company, focuses on the research and development of medicines in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant...
Where does MTPH.L trade?
Midatech Pharma plc (MTPH.L) trades on the London Stock Exchange.
What sector is MTPH.L in?
Midatech Pharma plc (MTPH.L) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Midatech Pharma plc?
Stephen A. Stamp is the chief executive officer of Midatech Pharma plc (MTPH.L).
Where is Midatech Pharma plc headquartered?
Midatech Pharma plc is headquartered in United Kingdom.
Does MTPH.L pay a dividend?
Midatech Pharma plc (MTPH.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did MTPH.L go public?
Midatech Pharma plc (MTPH.L) completed its initial public offering in 2014.